期刊文献+

Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification 被引量:2

下载PDF
导出
摘要 Global prevalence of coronavirus disease 2019(COVID-19)calls for an urgent development of anti-viral regime.Compared with the development of new drugs,drug repurposing can significantly reduce the cost,time,and safety risks.Given the fact that coronavirus harnesses spike protein to invade host cells through angiotensinconverting enzyme 2(ACE2),hence we see if any previous anti-virtual compounds can block spike-ACE2 interaction and inhibit the virus entry.The results of molecular docking and molecular dynamic simulations revealed that remdesivir exhibits better than expected anti-viral invasion potential against COVID-19 among the three types of compounds including remdesivir,tenofovir and lopinavir.In addition,a positive correlation between the surface area occupied by remdesivir and anti-viral invasion potential was also found.As such,the structure of remdesivir was modified by linking an N-benzyl substituted diamidine derivative to its hydroxyl group through an ester bond.It was found that this compound has a higher anti-viral invasion potential and greater specificity.
出处 《The Journal of Biomedical Research》 CAS CSCD 2020年第6期458-469,I0015-I0020,共18页 生物医学研究杂志(英文版)
  • 相关文献

参考文献5

二级参考文献26

  • 1Kotwani P, Kwarisiima D, Clark TD, et al. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study[J]. BMC Public Health, 2013,13(1): 1151.
  • 2Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study[J]. Am J Med 1995, 98(5):476-484.
  • 3New approaches to antiarrhythmic therapy, part II: emer- ging therapeutic applications of the cell biology of cardiac arrhythmias[J]. Circulation, 2001,104(24):2990-2994.
  • 4Makkar KM, Sanoski CA, Spinier SA. Role of angioten- sin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias[J]. Pharmaco- therapy, 2009,29(1):31-48.
  • 5Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis[J]. Am J Therb, 2008,15(1):36-43.
  • 6Anand K, Mooss AN, Hee TT, et al. Meta-analysis: inhi- bition of renin-angiotensin system prevents new-onset atrial fibrillation[J]. Am Heart J, 2006,152(2):217-222.
  • 7Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis[J]. J Am Coil Cardiol, 2005, 45(11):1832-1839.
  • 8Higgins JP, Thompson SG, Deeks JJ, et al. Measuring incon- sistency in meta-analyses[J]. BMJ, 2003,327(7414):557-560.
  • 9Armitage P, Berry G, Matthews JNS. Analysing Means and Proportions. Statistical Methods in Medical Research[J]. Blackwell Science Ltd 2008:83-146.
  • 10Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study[J]. J Am Coll Cardiol, 2005,45(5):712-719.

共引文献1318

同被引文献44

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部